Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) just unveiled an announcement.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced the execution of a Share Transfer Agreement to acquire a 10% equity interest in Finance Company from SIIC Dongtan. This strategic acquisition is expected to enhance the company’s financial capabilities and strengthen its market position in the pharmaceutical industry.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the pharmaceutical industry in China, focusing on the production and distribution of pharmaceutical products and healthcare services.
YTD Price Performance: -1.81%
Average Trading Volume: 4,601,117
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$66.94B
For detailed information about 2607 stock, go to TipRanks’ Stock Analysis page.